|
A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC
RECRUITINGPhase 2Sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd.
Actively Recruiting
PhasePhase 2
SponsorShanghai Hengrui Pharmaceutical Co., Ltd.
Started2026-10-07
Est. completion2028-12
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07798947
Summary
This study is an open-label, multicenter, phase II clinical study designed to evaluate the preliminary efficacy, safety, and tolerability of SHR-7787 in combination with Adebrelimab in patients with limited-stage small cell lung cancer.
Eligibility
Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria: 1. Voluntarily participate in this clinical study, understand the study procedures, and be able to sign the informed consent form (ICF) in writing. 2. Aged 18 to 75 years (inclusive), of any gender. 3. Histologically or cytologically confirmed unresectable limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemotherapy and radiation therapy. 4. ECOG performance status score of 0 or 1. 5. Estimated survival time of more than 3 months. 6. Have adequate bone marrow and organ function. 7. Female trial participants of childbearing potential must agree to use highly effective contraception from the time of signing the informed consent form until 6 months after the last dose of the investigational drug, and avoid donating eggs. Exclusion Criteria: 1. Combined small cell lung cancer or any transformed small cell lung cancer. 2. History of other malignancies within 5 years prior to the first dose of the study drug. 3. Severe cardiovascular or cerebrovascular diseases. 4. Bleeding symptoms of significant clinical relevance within 3 months prior to the first dose of the study drug. 5. Malignant pleural effusion or malignant pericardial effusion. 6. Severe infection within 4 weeks prior to the initiation of study treatment. 7. Active tuberculosis infection within 1 year prior to enrollment, identified by medical history or imaging examination. 8. History of immunodeficiency. 9. Active, known, or suspected autoimmune disease, or a history of autoimmune disease. 10. Prior treatment with immune checkpoint inhibitors (ICIs). 11. Undergone major organ surgery within 4 weeks prior to the first dose of the study drug. 12. Any other factors that, in the judgment of the investigator, may affect the study results or force premature termination of the study.
Conditions3
CancerLimited Stage Small Cell Lung CancerLung Cancer
Interventions2
Related trials
- A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer — Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC — Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy — Fudan University
- Reverse Triple Negative Immune Resistant Breast Cancer — Fudan University
- A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors — Shanghai Hengrui Pharmaceutical Co., Ltd.
- A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors — Shanghai Hengrui Pharmaceutical Co., Ltd.
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 2
SponsorShanghai Hengrui Pharmaceutical Co., Ltd.
Started2026-10-07
Est. completion2028-12
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07798947